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Abstract The relationship between glutathione deficiency, 
glycogen metabolism and ascorbate synthesis was investigated 
in isolated murine hepatocytes. Glutathione deficiency caused by 
various agents increased ascorbate synthesis with a stimulation 
of glycogen breakdown. Increased ascorbate synthesis from 
UDP-glucose or gulonolactone could not be further affected by 
glutathione depletion. Fructose prevented the stimulated glyco- 
genolysis and ascorbate synthesis caused by glutathione con- 
sumption. Reduction of oxidised glutathione by dithiothreitol 
decreased the elevated glycogenolysis and ascorbate synthesis in 
diamide or menadione treated hepatocytes. Our results suggest 
that a change in GSI-I/GSSG ratio seems to be a sufficient 
precondition of altering glycogenolysis and a consequent 
ascorbate synthesis. 
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I. Introduction 
The liver plays a central role in the antioxidant defence 
producing the most important water soluble antioxidants, 
GSH and - in the overwhelming majority of  organisms -
ascorbate for export. GSH and ascorbate are connected 
through a redox coupling. They can substitute and save 
each other in different species [1,2]. Recently it has been de- 
scribed that besides this redox connection there is a biosyn- 
thetic link: GSH deficiency produced in mice by in vivo ad- 
ministration of buthionine sulfoximine increases hepatic 
ascorbate synthesis [3]. 
In animals with the exception of primates, guinea pig and 
some other species ascorbate is produced in the uronic acid 
pathway in the liver or kidney from UDP-glucose through 
UDP-glucuronic acid. Three microsomal enzymatic steps are 
involved in this synthesis from UDP-glucuronic acid; glucuro- 
nic acid, glucuronolactone and gulonolactone are intermedi- 
ates in order [4]. The role of liver glycogen in substrate supply 
of a UDP-glucuronic acid consuming process such as glucu- 
ronidation has been shown previously [5]. Recently the depen- 
dence of ascorbate synthesis on glycogenolysis has been re- 
ported [6]. However, glycogenolysis  also induced by agents, 
which provoke GSH deficiency [7-9]. 
GSH depletion and the consequent alteration of the GSH/  
GSSG ratio can decrease the activity of enzymes involved in 
glycogen metabolism such as glycogen synthase [10-12] and 
glycogen phosphorylase phosphatase [13]. Therefore, a direct 
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relationship of GSH depletion, glycogenolysis and ascorbate 
synthesis was supposed in the liver. Experiments were under- 
taken to investigate the role of GSH depletion in glycogeno- 
lysis and ascorbate synthesis. GSH deficiency was provoked 
by various agents: the thiol oxidant, diamide [14], the strong 
NADPH consumer compound, menadione [15], the specific 
inhibitor of T-glutamylcysteine synthetase, buthionine sulfox- 
imine [16], the GSH conjugative acetaminophen [17] and di- 
butyryl cyclic AMP [18]. It was demonstrated that various 
agents which depleted GSH in hepatocytes, cause an increased 
ascorbate production via increased glycogenolysis. 
2. Materials and methods 
2.1. Materials 
Collagenase (type IV), ct,ct'-dipyridyl, dithiothreitol, Ellman's re- 
agent, glyoxylic acid, acetaminophen, e-buthionine-(S,R)-sulfoximine, 
diamide, dibutyryl cyclic AMP, menadione, saponin, UDP-glucose 
and gulonolactone were purchased from Sigma (St. Louis, MO, 
USA). Cyclic AMP assay kit was bought from Amersham Interna- 
tional plc (Amersham, UK). All other materials were of analytical 
grade. 
2.2. Preparation and incubation of isolated mouse hepatocytes 
CFLP male mice (25 35 g body weight, LATI, G6d611~, Hungary) 
fed ad libitum were used. Isolated hepatocytes were prepared by the 
collagenase perfusion method as described earlier [19]. Hepatocytes 
(3-5× 106 cells/ml) were incubated in Krebs-Henseleit bicarbonate 
buffer (pH 7.4) containing 2.5 mM CaC12, 1% albumin, 2.5 mM 
pyruvate and amino acids (1 mM each) and were stirred by constant 
bubbling with gas (O2:CO2, 95:5 v/v%) at 37°C. Glucose was not 
added to the medium for determination of glucose production which 
in this case indicates the rate of glycogen breakdown. Viability of the 
cells checked by the trypan blue exclusion test was about 90 95%. In a 
series of experiments hepatocytes were permeabilised by saponin as 
described earlier [20]. 
2.3. Measurement of metabolites 
Incubations were terminated by the addition of 0.05 volume of 
100% trichloroacetic acid for the determination of ascorbate. Ascor- 
bate content was measured by the method of Omaye et al. [21], based 
on the reduction of Fe 3+ with the oxidation of ascorbate and the 
subsequent determination of the Fe2+~zt,et'-dipyridyl complex. The 
samples for the measurement of glycogen were precipitated by adding 
10 volumes of 1 N HC1 [22]. Glycogen analysis was carried out by 
hydrolysis [22] and subsequent glucose measurement. Glucose was 
determined by the o-toluidine method [23] to avoid in vitro interfer- 
ence of acetaminophen or dithiothreitol and the glucose oxidase or 
hexokinase test systems. The GSH content of the suspension was 
determined according to Ball [24]. Dithiothreitol can react with Ell- 
man's reagent, therefore GSH content was measured by the GSH 
transferase assay when dithiothreitol was present in the incubations 
[25]. Intracellular cAMP concentration was measured by radioimmu- 
noassay [26]. Cell numbers were calculated on the basis of DNA 
content of hepatocytes determined according to [27]. 
2.4. Statistics 
All data were expressed as means + S.E.M. Statistical analysis was 
carried out using Student's t-test. 
All rights reserved. 
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Table 1 
Effect of various GSH depleting 
hepatocytes 
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agents on ascorbate production, intracellular cyclic AMP levels and glycogen breakdown of isolated murine 
Treatment GSH consumption cAMP content Glycogen breakdown Ascorbate production 
(pmol/min/106 cells) (pmol/106 cells) (nmol glucose unit/min/106cells) (pmol/min/106cells) 
none 102 + 5 410 1.57 + 0.33 55 + 18 
1 mM dibutyryl cyclic AMP 265+21'** N.D. 8.12+0.64"** 282+24*** 
0.1 mM diamide 499 + 24*** 476 7.41 + 0.82*** 271 _+ 8*** 
0.1 mM menadione 502 + 14"** 217 5.87 + 0.53*** 292 + 3*** 
5 mM buthionine sulfoximine 585 + 81"** 105 7.55 + 0.45*** 269 + 15"** 
5 mM acetaminophen 365 + 8*** 43 10.09 + 0.56*** 257 _+ 18"** 
GSH, glycogen and ascorbate contents were determined in suspensions of isolated murine hepatocytes before and 30 min after administration f
various GSH depleting agents. (Initial values were as follows: GSH 28.4 + 0.8 nmol/106 cells, glycogen 279.5 + 18.8 nmol glucose unit/106 cells, 
ascorbate 3.9 + 0.8 nmol/10 e cells; means_+ S.E.M. of 27 measurements.) Intracellular cAMP content was measured at 30 rain. Values are given as 
means of 3-15 experiments (cAMP measurement n=2). Statistically significant differences among values gained in treated cells versus corresponding 
untreated controls: ***P< 0.01. N.D., not determined. 
3. Results 
Different GSH depleting agents were administered to sus- 
pensions of isolated murine hepatocytes. These compounds 
caused a 25-60% decrease in GSH level during 30 min incu- 
bations. The GSH consumption was the highest in mena- 
dione, diamide or buthionine sulfoximine treated hepatocytes 
(Table 1). At  the same time an about  fivefold stimulation of 
ascorbate synthesis could be observed. Al though 1 mM dibu- 
tyryl cyclic AMP decreased the cellular GSH less, it also 
caused a high ascorbate product ion in hepatocytes (Table 1). 
The effects of the various GSH depleting agents on intra- 
cellular cAMP levels were also investigated. While diamide 
moderately increased the cAMP concentrat ion i hepatocytes, 
the other GSH consuming compounds decreased intracellular 
cAMP levels (Table 1). 
Table 1 shows that all the GSH depleting agents adminis- 
tered enhanced glycogenolysis markedly. Acetaminophen had 
the strongest glycogen consuming effect, stronger than that of 
1 mM dibutyryl cyclic AMP.  
To investigate the causal connection between GSH deple- 
t ion induced glycogenolysis and ascorbate synthesis two dif- 
ferent experimental pproaches were used. First, fructose was 
administered to inhibit glycogen breakdown [28] and activate 
glycogenesis [29]. Addit ion of 4 mM fructose did not alter the 
GSH consumpt ion caused by different agents but as expected 
it prevented their glycogenolytic effect and rather glycogen 
formation occurred (Table 2). Fructose prevented the stimula- 
t ion in ascorbate product ion (Table 2). 
Second precursors of the ascorbate synthesis originated i- 
rectly or indirectly from glycogenolysis were substituted with 
the addit ion of UDP-glucose or gulonolactone. Addit ion of 
UDP-glucose to permeabil ised cells or gulonolactone to intact 
cells stimulated the synthesis of ascorbate [30] independently 
of the addit ion of various GSH depleting agents (Table 3). 
Under  these experimental condit ions GSH depletion was de- 
tected upon addit ion of GSH depleting agents (data not 
shown). 
Among the various GSH depleting agents diamide and me- 
nadione have strong oxidative effects causing a decrease of the 
GSH/GSSG ratio. GSSG oxidised enzymes can be reactivated 
with dithiothreitol [10-12]. Therefore, the effect of dithiothrei- 
tol on glycogen metabol ism and ascorbate product ion was 
investigated in diamide or menadione treated isolated mouse 
hepatocytes. 2 mM dithiothreitol was added to the suspen- 
sions following 30 min incubations with 0.1 mM diamide or 
0.1 mM menadione and the incubations were continued 
further for 20 min. As shown in Table 4 after addit ion of 
dithiothreitol the stimulated glycogenolysis and ascorbate pro- 
duction declined both in diamide and in menadione treated 
hepatocytes. 
4. Discussion 
This paper demonstrates that GSH deficiencies of various 
origin result in an increased glycogen breakdown and stimu- 
lated ascorbate synthesis (Table 1). The metabolic onnection 
between GSH deficiency and ascorbate synthesis has been 
Table 2 
Prevention of the stimulation of ascorbate production by administration of fructose in glutathione depleted isolated mouse hepatocytes 
Treatment GSH consumption Glycogen breakdown Ascorbate production 
(pmol/min/106cells) (nmol glucose unit/min/106 cells) (pmol/min/106 cells) 
none 
4 mM fructose 
4 mM fructose 
+ 1 mM dibutyryl cyclic AMP 
4 mM fructose + 0.1mM diamide 
4 mM fructose + 0.1mM menadione 
4 mM fructose 
+ 5 mM buthionine sulfoximine 
4 mM fructose 
+5 mM acetaminophen 
98+54 1.57+0.33 55+ 18 
128 _+ 64 -3.20 _+ 1.17"** 30 + 10 
305 + 36** -2.96 + 0.39*** 64 + 12 
553 + 36*** - 1.72 + 0.55** 62 + 24 
568 + 62*** -3.29 + 0.24*** 45 + 18 
596 _+ 22*** -3.98 + 0.82*** 76 + 34 
308 + 25** -3.57 + 0.63*** 58 + 29 
Isolated hepatocytes were incubated in the presence of 4 mM fructose and various GSH depleting compounds. For experimental details and initial 
values see the legend of Table 1. Data are given as means + S.E.M. of 4 experiments. Statistically significant differences between treated cells versus 
untreated controls: **P < 0.02, ***P < 0.01. 
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Table 3 
Ascorbate synthesis from UDP-glucose or gulonolactone in the presence of different glutathione depleting agents 
175 
Treatment Ascorbate production (pmol/mirdl06 cells) 
permeabilised cells, 5 mM UDP-glucose intact cells, 5 mM gulonolactone 
none 266 _+ 20 1844 + 465 
1 mM dibutyryl cyclic AMP 253 _+ 33 2107 + 949 
0.1 mM diamide 306 + 23 2175 + 929 
0.1 mM menadione 266 + 9 2246 + 312 
5 mM buthionine sulfoximine 261 +28 1853 + 57 
5 mM acetaminophen 297 + 16 1908 + 810 
Isolated mouse hepatocytes were prepared, thereafter half of the cells were permeabilised by 0.005% of saponin for 5 min. After the permeabilisa- 
tion 5 mM UDP-glucose was added to the cells. In the absence of UDP-glucose ascorbate production of permeabilised hepatocytes was 12 +_ 3 
pmol/min/10%ells. In another series of experiments gulonolactone was added to the remaining part of the hepatocyte suspension. For the control 
values of ascorbate production in intact cells see Table 1. The cells were incubated further in the presence or absence of different GSH depleting 
compounds. Ascorbate production was determined. Data are given as means + S.E.M. of 4 experiments. 
reported first based on in vivo experiments in livers of GSH 
deficient mice [3]. Our in vitro data support the assumption 
that in GSH deficiency there is de novo ascorbate synthesis 
(Table 1). Previous findings according to which the enhanced 
glycogenolysis has been responsible for the stimulation of as- 
corbate production [6] can be further supported by the follow- 
ing observations: (i) inhibition of  glycogenolysis by fructose 
does not modify the GSH depleting effect of agents applied, 
but prevents their stimulation on ascorbate synthesis (Table 
2), (ii) ascorbate production from UDP-glucose or gulonolac- 
tone cannot be further increased by GSH depletion (Table 3). 
It is concluded that the regulated pathway in this sequence of 
events is glycogenolysis, as the mechanism of GSH depletion 
does not affect the subsequent process. 
Hepatic glycogenolysis regulated mainly through cAMP 
and Ca 2+ dependent mechanisms. Among the GSH depleting 
agents diamide and menadione have been reported to accu- 
mulate cAMP in the cells [31,32]. On the other hand diamide 
is an inhibitor of cyclic AMP dependent protein kinase A [33]. 
Under our experimental conditions menadione, like buthio- 
nine sulfoximine and acetaminophen, decreases cAMP levels 
of isolated hepatocytes (Table 1). Thus, it is concluded that 
cAMP mediation itself cannot be responsible for stimulated 
glycogenolysis n GSH deficiencies. Another possibility to in- 
crease hepatic glycogenolysis the elevation of cytosolic free 
Ca 2+, a frequent consequence of GSH depletion. The ability 
of menadione to increase cytoplasmic Ca 2+ concentration is
well known [34,35], like that of  acetaminophen. Disruption of 
Ca 2+ pumping by acetaminophen leads to higher cytosolic 
Ca 2+ levels with the activation of  glycogen phosphorylase 
[36]. However, there is no exact and direct evidence concern- 
ing the effect of  diamide or buthionine sulfoximine on intra- 
cellular Ca 2+ mobilisation and under our experimental cir- 
cumstances menadione increased glycogenolysis even in 
Ca 2+ depleted hepatocytes (data not shown). It should be 
noted, however, that oxidation of  GSH increases the sensitiv- 
ity of IP3 receptors [37]. Thus, a primary role of GSH was 
supposed in the regulation of glycogenolysis under various 
GSH deficient conditions. 
GSH depletion and/or change of GSH/GSSG ratio can in- 
fluence glycogen metabolism directly. The increased glycogen 
breakdown and ascorbate synthesis is diminished after addi- 
tion of dithiothreitol both in diamide and in menadione trea- 
ted hepatocytes (Table 4). Mixed disulfide formation between 
glycogen synthase and GSSG leads to inactivation of the en- 
zyme and causes its dissociation from the glycogen particle 
[10-12], moreover, stimulation of glycogen phosphorylase 
via inhibition of phosphorylase phosphatase by GSSG has 
also been reported [13]. Therefore, in shortage of GSH glyco- 
gen metabolism can be shifted to the direction of glycogen 
breakdown and consequently there is an oversupply of 
UDP-glucose. Reduction of GSSG with sulfhydryl reagents 
such as dithiothreitol promotes restoration and reactivation 
of the GSSG-oxidised glycogen synthase [38-40], therefore it 
can lower UDP-glucose supply. These findings confirm the 
suggestion that a change of the GSH/GSSG ratio is a neces- 
sary and sufficient precondition for altering glycogenolysis 
and the consequent glycogenolysis-linked ascorbate synthesis. 
Other effects of GSH depletion (increased cytosolic [Ca 2+] 
and, in some cases, elevation of cAMP level) may also con- 
tribute to the increased glycogenolysis. 
In summary, the present study shows that besides the redox 
connection between GSH and ascorbate another interrelation- 
ship also exists: GSH deficiency induces glycogen breakdown 
Table 4 
Effect of dithiothreitol n glycogen breakdown and ascorbate synthesis of isolated murine hepatocytes treated with menadione or diamide 
Treatment GSH consumption(pmol/min/106 cells) Glycogen breakdown Ascorbate production 
(nmol glucoseunit/min/106 cells) (pmol/mirdl06 cells) 
before after before 2 mM after 2 mM before after 
dithiothreitol dithiothreitol 
control 91 + 49 -57 + 8 + 1.63 + 0.14 1.51 _+ 0.07 23 + 1 28 + 1 
0.1 mM diamide 522 + 179* -862 + 60 ***++t 9.44 + 0.52*** 4.96 + 0.22 *+it 304 + 8*** 118 + 5 *ttt 
0.1 mM menadione 593 + 73 . . . .  730 + 56 ***++t 5.29 + 0.68* 2.25 + 0.10 +t+ 315 _+ 2*** 85 + 4 *++t 
Isolated hepatocytes were incubated in the presence of 0.1 mM diamide or 0.1 mM menadione for 30 min. 2 mM dithiothreitol was added at 30 min 
and incubations were continued further for 20 min. GSH consumption, glycogen breakdown and ascorbate production were determined before and 
after administration of dithiothreitol. Data were expressed as means _+ S.E.M. of 34  experiments. Significant difference compared to the corre- 
sponding controls: *P < 0.05, ***P < 0.01 and between the values before or after addition of dithiothreitol: +P < 0.05, +t+p < 0.01. 
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and de novo ascorbate synthesis independently of the origin 
of GSH depletion. The ascorbate production - stimulated by 
GSH deficiency - represents a pathway serving a useful bal- 
ance of the main antioxidants, thus, the liver is able to main- 
tain a continuous antioxidant defence in cases of short-term 
oxidative challenges. 
Acknowledgements." Mrs. Gizella Ferencz is gratefully acknowledged 
for her skilful technical assistance. We thank Emilia Maellaro (Istituto 
di Patologia Generale, University of Siena, Siena, Italy) for critical 
reading of the manuscript. This work was supported by OTKA and 
by the Ministry of Welfare, Hungary. 
References 
[1] Szent-Gy6rgyi, A. (1928) Biochem. J. 22, 1387-1409. 
[2] M~.rtensson, J., Han, J., Griffith, O.W. and Meister, A. (1993) 
Proc. Natl. Acad. Sci. USA 90, 317-321. 
[3] M~rtensson, J. and Meister, A. (1992) Proc. Natl. Acad. Sci. 
USA 89, 11566-11568. 
[4] Levine, M. (1986) New Engl. J. Med. 314, 892-902. 
[5] B~.nhegyi, G., Garz6, T., Antoni, F. and Mandl, J. (1988) Bio- 
chim. Biophys. Acta 967, 429-435. 
[6] Braun, L., Garz6, T., Mandl, J. and B~inhegyi, G. (1994) FEBS 
Lett. 352, 4-6. 
[7] Plummer, J.L., Smith, B.R., Sies, H. and Bend, J.R. (1981) Meth- 
ods Enzymol. 77, 50-59. 
[8] Bellomo, G., Thor, H. and Orrenius, S. (1984) FEBS Lett. 168, 
38-42. 
[9] Redegeld, F.A.M., Moison, R.M.W., Barentsen, H.M., Koster, 
A.S. and Noordhoek, J. (1990) Arch. Biochem. Biophys. 280, 
130-136. 
[10] Lau, K.H.W. and Thomas, J.A. (1983) J. Biol. Chem. 258, 2321 
2326. 
[11] Ernest, M.J. and Kim, K.H. (1973) J. Biol. Chem. 248, 1550- 
1555. 
[12] Ernest, M.J. and Kim, K.H. (1974) J. Biol. Chem. 249, 5011 
5018. 
[13] Usami, M., Matsushita, H. and Shimazu, T. (1980) J. Biol. 
Chem. 255, 1928-1931. 
[14] Kosower, N.S., Kosower, E.M., Werthein, B. and Correa, W.S. 
(1969) Biochem. Biophys. Res. Commun. 37, 593 596. 
[15] Di Monte, D., Ross, D., Bellomo, G., Ekl6w, L. and Orrenius, S. 
(1984) Arch. Biochem. Biophys. 235, 334-342. 
[16] Griffith, O.W. (1981) Methods Enzymol. 77, 59-63. 
[17] Savides, M.C. and Oehme, F.W. (1983) J. Appl. Toxicol. 3, 96- 
111. 
[18] Higashi, T., Tateishi, N., Naruse, A. and Sakamoto Y. (1976) 
Biochem. Biophys. Res. Commun. 68, 128~1286. 
[19] Mandl, J., Garz6, T., M~sz~ros, K. and Antoni, F. (1979) Bio- 
chim. Biophys. Acta 586, 560-567. 
[20] Bfinhegyi, G., Garz6, T., Fulceri, R., Benedetti, A. and Mandl, J. 
(1993) FEBS Lett. 328, 149 152. 
[21] Omaye, S.T., Turnbull, J.D. and Sauerberlich, H.E. (1979) Meth- 
ods Enzymol. 62, 3-7. 
[22] Passonneau, J.V. and Lauderdale, V.R. (1974) Anal. Biochem. 
60, 405-412. 
[23] Hultman, E. (1959) Nature 183, 108-109. 
[24] Ball, C.R. (1966) Biochem. Pharmacol. 15, 809-816. 
[25] Brigelius, R., Muckel, C., Akerboom, T.P.M. and Sies, H. (1983) 
Biochem. Pharmacol. 32, 2529-2534. 
[26] Steiner, A.L., Pagliara, A.S., Chase, L.R. and Kipnis, D.M. 
(1972) J. Biol. Chem. 247, 1114-1120. 
[27] Burton, K. (1956) Biochem. J. 62, 315 323. 
[28] van den Berghe, G., Hue, L. and Hers, H.G. (1973) Biochem. J. 
134, 637-645. 
[29] Whitton, P.P. and Hems, D.A. (1975) Biochem. J. 150, 153-165. 
[30] B~mhegyi, G., Csala, M., Braun, L., Garz6, T. and Mandl, J. 
(1996) FEBS Lett. 381, 39-41. 
[31] Wedner, H.J. (1980) Biochim. Biophys. Acta 628, 407-418. 
[32] Fain, J.N. (1971) Mol. Pharmacol. 7, 465-47928. 
[33] Von Tersch, I.J., Mendicino, I., Pillion, D.J. and Leibach, F.J. 
(1975) Biochem. Biophys. Res. Commun. 64, 433~40. 
[34] Jewell, S., Bellomo, G., Thor, H., Orrenius, S. and Smith, M.T. 
(1982) Science 217, 1257-1259. 
[35] Nicotera, P., McConkey, D., Svensson, S.A., Bellomo, G. and 
Orrenius, S. (1988) Toxicology 52, 55-63. 
[36] Long, R.M. and Moore, L. (1988) J. Biochem. Toxicol. 3, 353- 
362. 
[37] Renard-Rooney, D.C., Joseph, S.K., Seitz, M.B. and Thomas, 
A.P. (1995) Biochem. J. 310, 185-192. 
[38] Mehendale, H.M., Svensson, S.A., Baldi, C. and Orrenius, S. 
(1985) Eur. J. Biochem. 149, 201-206. 
[39] Mirabelli, F., Salis, A., Vairetti, M., Bellomo, G., Thor, H. and 
Orrenius, S. (1989) Arch. Biochem. Biophys. 270, 478-488. 
[40] Redegeld, F.A.M., Moison, R.M.W., Koster, A.S. and Orrenius, 
S. (1984) Arch. Biochem. Biophys. 235, 343-350. 
